Skip to content

Study Details

EPX-100: A Study Drug for People with Dravet Syndrome

(IRB#: IRB_00155489)

Dravet Syndrome is a rare, severe epilepsy disease that appears during the first year of life. EPX-100 is a study drug to help people with this disease. Research is needed to learn the safety and effectiveness of the study drug. Information we gain may aid future patients.


  • All genders
  • All Ages
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: All Ages

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 2 to 18 years and older
  • Seizures before 18 months of age
  • Normal development before seizures occurs
  • Birth control may be required
  • In-person at the University of Utah

Exclusion Criteria

  • Active suicidal plan/intent or thoughts in the past 6 months
  • Suicide attempt(s) in the past 3 years
  • Any other medical issue such as heart disease
  • Seizures after drug and alcohol use, infection, or other diseases
  • Using another study drug at any time of participation

Will I be paid for my time?


For more information contact:

Laura Beeler


IRB#: IRB_00155489

PI: Angela Peters

Department: NEUROLOGY

Approval Date: 2023-02-22 07:00:00

Study Categories: Brain Health Studies

Specialties: Neurology

Last Updated: 6/8/23